Cryo-Cell Reports Mixed Financial Results: Revenue Up, Net Income Down Amid Rising Costs

Cryo-Cell International, Inc. (OTCMKTS: CCEL) recently reported its financial results for the six months ended May 31, 2025. Below are the key aspects from their income statement, highlighting both positive and negative elements.

• Total Revenue: $15,897,723, slightly up from $15,895,046 in the previous year.
• Processing and Storage Fees: Remained relatively stable at $15,737,607 compared to $15,771,022, reflecting a 4% increase in recurring annual storage fees, but a 15% decrease in new specimens processed.
• Public Cord Blood Banking Revenue: Increased to $124,767 from $85,190, indicating better customer demand.
• Cost of Sales: Reduced to $3,841,127 from $4,185,218, a decrease of 8%, primarily due to process enhancements and lower operating costs.
• Selling, General and Administrative Expenses: Increased to $8,896,142 from $8,352,129, a 7% rise reflecting higher marketing and personnel costs.
• Research & Development Expenses: Down from $743,974 to $229,854, signaling a reduction in spending on initiatives related to the Duke License Agreement.
• Depreciation and Amortization: Significantly increased to $381,955 from $92,984, attributed to a new facility incurred in Durham.
• Interest Expense: Rose sharply to $1,046,088 from $585,732 due to higher debt levels and costs of the revolving credit facility.
• Net Income: Dropped to $638,640 from $1,212,031, reflecting the impact of increased interest expenses and lower effective tax impacts.
• Net Income Per Share (Basic): $0.08, down from $0.15, indicating a dilution in earnings amidst increasing costs.

Positive Aspects:

• Stable revenue generation with an increase in public banking, highlighting better service uptake.
• Significant reduction in costs of sales suggests improved efficiency in processing and minimal waste.

Negative Aspects:

• Declining net income and earnings per share point toward financial strain primarily driven by increased interest costs and fixed expenditures.
• Decreased investment in R&D due to challenges related to the Duke License Agreement, raising concerns over future growth and innovation.
• Rising administrative costs may overshadow potential revenue gains, affecting overall profit margins.

Going forward, Cryo-Cell International is poised at a critical juncture influenced by its ongoing legal disputes and market conditions. Investors should watch how the company navigates these challenges to gauge future performance and sustainability.